

1 Title page

2

3

4 The Gene Knockout of Angiotensin II Type 1a Receptor Improves High-fat Diet-
5 Induced Obesity in rat *via* Promoting Adipose Lipolysis

6

7 AT1aR knockout improves obesity

8

9 Aiyun Li ⁺, Wenjuan Shi ⁺, Jin Wang, Xuejiao Wang, Yan Zhang, Zhandong Lei, Xiang-Ying Jiao ^{*}

10

11

12

13 Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, and the

14 Department of Physiology, Shanxi Medical University, Taiyuan 030001, China

15

16

17 ^{*} Correspondence author. Tel/Fax: +86-351-3985178;

18 E-mail address: jiaoxy@sxmu.edu.cn; ORCID: 0000 0003 1182 9052

19

20

21 ⁺ These authors contributed equally to this work.

22

23 **Abstract**

24 *Aims:* The renin-angiotensin system (RAS) is over-activated and the serum angiotensin II (Ang II)
25 level increased in obese patients, while their correlations were incompletely understood. This study
26 aims to explore the role of Ang II in diet-induced obesity by focusing on adipose lipolysis.

27 *Methods:* Rat model of AT1aR gene knockout were established to investigate the special role of Ang
28 II. Wild-type (WT) and AT1aR gene knockout (AT1aR^{-/-}) SD rats were fed with normal diet or high-fat
29 diet for 12 weeks. Adipose morphology and adipose lipolysis were examined.

30 *Results:* AT1aR deficiency activated lipolysis-related enzymes and increased the levels of NEFAs and
31 glycerol released from adipose tissue in high-fat diet rats, while did not affect triglycerides synthesis.
32 Besides, AT1aR knockout promoted energy expenditure and fatty acids oxidation in adipose tissue.
33 cAMP levels and PKA phosphorylation in the adipose tissue were significantly increased in AT1aR^{-/-}
34 rats fed with high-fat. Activated PKA could promote adipose lipolysis and thus improved adipose
35 histomorphology and insulin sensitivity in high-fat diet rats.

36 *Conclusions:* AT1aR deficiency alleviated adipocyte hypertrophy in high-fat diet rats by promoting
37 adipose lipolysis via cAMP/PKA pathway, and thereby delayed the onset of obesity and related
38 metabolic diseases.

39 *Key Words:* Angiotensin II type 1a receptor, obesity, adipose lipolysis, cAMP/PKA

40

41 **1. Introduction**

42 Obesity is a growing health problem that induces major metabolic disorders, such as diabetes,
43 cardiovascular disease, and hypertension. Obesity has been officially listed as a disease by the World
44 Health Organization in 2000. It has been predicted that more than 57.8% adults and about 3.3 billion

45 people worldwide will facing overweight or obesity problems by 2030[1]. With an increasing
46 prevalence of obesity, it is urgent to elucidate the pathophysiological mechanism for obesity and
47 develop effective therapy strategies for treatment of obesity and its associated disorders.

48 Adipose tissue plays major role in the development of obesity. Excess energy is stored in the
49 adipose tissue in the form of triacylglycerol (TAG), while fatty acid mobilization via lipolysis releases
50 fatty acids to increase hepatic fatty acid oxidation for energy supply[2]. Physiologically, adipose tissue
51 maintains a dynamic balance between lipid synthesis and decomposition. However, adipose tissue
52 stores excess energy by expansion and remodeling when the storage capacity of adipocytes is exceeded
53 in response to overfeeding, resulting in fat accumulation and adipocyte hypertrophy[3, 4]. Therefore,
54 inhibiting adipocyte hypertrophy can be an effective strategy for obesity treatment.

55 The renin-angiotensin system (RAS) is a dynamic physiologic system and its classic function is to
56 regulate blood pressure and fluid and electrolyte balance. Angiotensin-converting enzyme inhibitor
57 (ACEI) and angiotensin II receptor blockers (ARB) has been clinically used as antihypertensive drugs
58 and play a crucial role in the treatment of cardiovascular diseases such as hypertension and heart
59 failure. However, it has been found that these drugs have a positive effect in metabolic diseases such as
60 obesity, insulin resistance and diabetes^[5, 6], indicating the relations between RAS and metabolic
61 diseases. Animal studies have shown that mice with renin gene knockout are resistant to diet-induced
62 obesity[7]. Besides, excessive activation of RAS is a common feature in obese patients[8, 9], and the
63 serum levels of angiotensinogen (AGT) and angiotensin II (Ang II) in the obese are higher than those
64 in normal population^[10-12]. Adipose tissue is the most abundant source of AGT outside liver. It is
65 showed that AGT expression increased in the adipose tissue of obese animal models and adipocyte-
66 specific enhancement of AGT lead to insulin resistance[13], indicating the special role of adipose tissue

67 RAS in regulation of metabolic homeostasis. Adipose RAS has attracted more and more attention due
68 to its close relationship with obesity and adipose dysfunction over the years[14-16]. However, the
69 underline mechanism by which RAS activation in adipose tissue results in obesity and other metabolic
70 diseases remain unclear.

71 Angiotensin II (Ang II), the predominant peptide of the RAS, exerts effects mainly by binding
72 with angiotensin type 1 receptor (AT1R) in adipose tissue[14]. Hence, we established an obese rat
73 model with AT1aR gene knockout to explore the role of adipose RAS in the develop process of
74 obesity. The results showed that the gene knockout of AT1aR ameliorated adipocyte hypertrophy by
75 promoting adipose lipolysis, and thereby improving obesity and related metabolic disorders. Our
76 finding suggests that targeting RAS signaling in adipose tissue may become a promising therapy
77 avenue for obesity and associated metabolic abnormalities.

78 **2. Materials and Methods**

79 **2.1 Experimental animals**

80 Wild type male Sprague-Dawley (SD) rats purchased from the Experimental Animal Center of
81 Shanxi Medical University and AT1aR^{-/-} male SD rats (Nanjing University-Nanjing Institute of
82 Biology) were all fed in the SPF laboratory animal environmental facilities with 12 h light/dark cycles
83 under standard room temperature (22 ± 2°C) and free access to water and food. AT1aR gene knockout
84 rats have been verified as homozygous by polymerase chain reaction (PCR) (S1 Fig). All animal
85 experiments were in accordance with the guidelines for the management of animals for medical
86 experiments issued by the Ministry of Health of the People's Republic of China (No. 55) and animal
87 ethics standards of Shanxi Medical University, and approved by the ethics committee.

88 4-week male wild type (WT) rats and AT1aR^{-/-} rats were randomly divided into normal diet group

89 (ND) and high-fat-diet group (HFD). The HFD group rats were fed with 60% high-fat feed (D12492,
90 Whitby Technology Co., Ltd. Beijing, China) and the ND group rats were fed with normal feed for 12
91 weeks. Body weight was recorded weekly. At the end of feeding, rats were fasted overnight and
92 anesthesia, blood sample was collected from the abdominal aorta for the assay of blood glucose,
93 nonesterified free fatty acids (NEFAs), triglyceride (TG), total cholesterol (T-CHO), low-density
94 lipoprotein (LDL) and high-density lipoprotein (HDL) contents with commercial kits (Jiancheng
95 Bioengineering Institute, Nanjing, China). Serum glycerol content was measured with glycerol (liquid
96 sample) enzymatic determination kit (Applygen Gene Technology Co., Ltd, Beijing). Epididymal
97 adipose tissue were isolated immediately or stored at minus 80 degrees Celsius until analysis.
98 Epididymal fat index were calculated as the ratio of epididymal fat weight to the body weight.

99 **2.2 Glucose tolerance test and insulin tolerance test**

100 For glucose tolerance test, rats were fasted overnight and administrated with glucose (2 g/kg) by
101 gavage. For insulin tolerance test, rats were fasted for 6h and intraperitoneally injected insulin (1
102 IU/kg). Blood glucose contents at 0 min, 15 min, 30 min, 60 min, 90 min, and 120 min were recorded
103 and blood glucose area under curve (AUC) was calculated.

104 **2.3 Blood pressure measurement**

105 At the end of 12-week feeding, rats were anesthetized and blood pressure were measured by
106 carotid artery cannulation and monitored with the BL-420 system.

107 **2.4 Morphological examination of adipose tissue**

108 Isolated epididymal adipose tissue was fixed with 4% paraformaldehyde, dehydrated with gradient
109 alcohol and then embedded in paraffin. Embedded wax block was sliced and epididymal sections were
110 stained with hematoxylin for 20 min and with eosin for 15 min, respectively. After sealing slide with

111 neutral gum, the morphology changes of adipocytes were visualized using optical microscope
112 (Olympus, Japan) and the cross-sectional area of adipocytes were calculated with Image J software.

113 **2.5 Quantitative real time RT-PCR**

114 Total mRNA of epididymal adipose tissue was extracted with Trizol (Takara Bio Inc., Japan). The
115 concentration and purity of extracted total mRNA were measured using NANODROP ONE (Thermo
116 Scientific, USA). cDNA was synthesized with the PrimeScriptTMRT reagent kit (Takara Bio Inc.,
117 Japan) following the manufacturers' instructions. Relative quantitative PCR was conducted with a TB
118 Green Primer Ex Taq II (Takara Bio Inc., Japan) using LightCycler® 96 Real-Time PCR System
119 (Roche, USA). The primer sequences were obtained from Takara and listed in supplementary Table 1.
120 Gene expressions were normalized with β -actin. Statistically relative quantification was analyzed with
121 equation $2^{-\Delta\Delta CT}$. Ct is the threshold cycle to detect fluorescence.

122 **Table 1**

123 Primer sequences used for quantitative real time RT-PCR

Name	Forward Primer (5'-3')	Reverse Primer (5'-3')
FAS	ACCTCATCACTAGAAGCCACCAG	GTGGTACTTGGCCTTGGGTTTA
ACC	TACAACGCAGGCATCAGAAG	TGTGCTGCAGGAAGATTGAC
CPT1a	CTGCCAGTTCATTAAGCCACA	CAGCTATGCAGCCTTTGACTACCA
PPAR α	GGCAATGCACTGAACATCGAG	GCCGAATAGTTCGCCGAAAG
PPAR δ	TGGCCCTGTTCCTAGAATTGATG	GCAAACCTCTGCCTGTGAGCTG
Dio2	CTGTGGTTGGATGTAGTCACACGA	CTTGCACCAGGACCCAAATG
β -actin	ACGGTCAGGTCATCACTATCG	GGCATAGAGGTCTTTACGGATG

124 **2.6 Measurement of free fatty acids and glycerol in adipose tissue**

125 At the end of 12-week feeding, rats were anesthetized and sterilized with alcohol. Epididymal
126 adipose tissue was isolated and 200 mg adipose tissue was weight and cut into pieces, and then

127 incubated in serum-free DMEM for 24 hours. DMEM was collected to measure NEFAs and glycerol
128 contents in the supernatant with commercial Kits following the manufacturer's instructions.

129 **2.7 Measurement of cAMP concentration**

130 Epididymal adipose tissue supernatants were obtained by homogenate and centrifugation. Cyclic
131 AMP in the supernatants were measured using cAMP assay kit (4339, Cell Signaling Technology)
132 according to the manufacturer's protocol.

133 **2.8 Western blot analysis**

134 Epididymal adipose tissue was homogenized with a tissue grinder at 4°C temperature and the
135 lysate were centrifugation at 12000 rpm for 20 minutes. The protein concentrations were measured
136 with BCA kit (KeyGEN BioTECH Corp., Ltd, Nanjin, China). The protein samples were denatured,
137 separated by SDS-PAGE and then transferred to the PVDF membrane. Membranes were blocked with
138 5% skim milk or bovine serum albumin (BSA) for 3 hours, and then incubated overnight at 4°C with
139 specific primary antibodies as follows: ATGL (2138S, Cell Signaling Technology), P-HSL^(ser660)
140 (4126S, Cell Signaling Technology), HSL (4107S, Cell Signaling Technology), P-GSK-3 β ^(ser9) (5558S,
141 Cell Signaling Technology), GSK-3 β (9315S, Cell Signaling Technology), β -actin (AP0060, Bioworld)
142 and PKA (5842S, Cell Signaling Technology). Membranes were washed and incubated with secondary
143 antibodies (BA1054, BOSTER Biological Technology) at room temperature for 3 hours. After
144 washing, membranes were exposed by Super ECL Prime (SEVEN BIOTECH) with ChemiDoc™
145 Imaging System (BIO-RAD, USA). The images were analyzed quantitatively by densitometry with
146 Image J software.

147 **2.9. Statistical analysis**

148 Results were shown as mean \pm SEM. Data were analyzed by using Student's t test for comparison

149 the difference of two groups and the comparison among multiple groups was analyzed by one-way
150 ANOVA. GraphPad Prism 6 was used for statistical analysis. A value of $p < 0.05$ was considered
151 statistically significant.

152 **3. Results**

153 **3.1 AT1aR knockout improved insulin sensitivity and metabolic disorders in high-fat diet rats**

154 Glucose tolerance test and insulin tolerance test are important indicators that generally to be used
155 to measure glucose tolerance and insulin sensitivity, respectively[17]. In response to glucose load or
156 insulin injection, there was no significant differences between AT1aR^{-/-} rats and WT rats with normal
157 diet, while the area under the curve (AUC) in HFD-fed AT1aR^{-/-} rats was significantly lower than that
158 in the HFD-fed WT rats (Fig 1A, B), indicating that AT1aR knockout improved insulin sensitivity in
159 high-fat-diet rats. Consistent with this, AT1aR knockout reduced the fasting blood glucose compared
160 with WT rats fed with high-fat-diet (Fig 1C). Moreover, rats blood pressure was monitored through
161 carotid artery intubation and the result showed that AT1aR gene knockout could reduce hypertension
162 caused by high-fat feeding (Fig 1D).

163 Next, lipid metabolism-related indicators in serum were detected with commercial kits. The
164 results showed that serum levels of TG, T-CHO, NEFAs, glycerol, LDL and HDL in high-fat diet WT
165 rats were significantly higher than those of WT rats fed with normal diet, whereas these alterations
166 were significantly reversed by AT1aR gene knockout, demonstrating that AT1aR knockout improved
167 metabolic disorders in obese rats (Fig 1E-J). Besides, serum LDL level of AT1aR^{-/-} rats were also
168 lower than that of the WT rats fed with normal diet (Fig 1I).

169 **Fig 1. AT1aR knockout improved insulin resistance and metabolic disorders in high-fat diet**
170 **rats.** A: Oral glucose tolerance test (OGTT) curve and area under the curve. B: Insulin tolerance test

171 (ITT) curve and area under the curve. C: Fasting blood glucose (FBG). D: Blood pressure. E: Serum
172 triglyceride (TG) levels. F: Serum total cholesterol (T-CHO). G: Serum free fatty acid. H: Serum
173 glycerol. I: Serum low-density lipoprotein (LDL). J: Serum high-density lipoprotein (HDL). * $p < 0.05$
174 vs WT-ND rats; # $p < 0.05$ vs WT-HFD rats. Data were presented as Mean \pm S.E.M. n = 6

175 **3.2 AT1aR knockout alleviated high-fat diet-induced adipocyte hypertrophy**

176 Body weight of rats were recorded weekly and the results showed that body weight gain of WT
177 rats were increased by high-fat diet feeding, while body weight gain of high-fat diet AT1aR^{-/-} rats were
178 much lower than that of high-fat diet WT rats (Fig 2A, B). Epididymal adipose tissues were isolated
179 and their physical morphology were photographed. As showed in Fig 2C, physical morphology of
180 epididymal adipose tissue in AT1aR^{-/-} rats was smaller than that of WT rats. Besides, the epididymal
181 fat index of high-fat diet AT1aR^{-/-} rats was also decreased compared to high-fat diet WT rats (Fig 2D).
182 Moreover, the histomorphology of adipose were visualized by HE staining and adipocyte area of WT
183 rats were significantly enlarged by high-fat diet feeding, whereas this alteration were significantly
184 reversed in high-fat diet AT1aR^{-/-} rats (Fig 2E). These results indicated that AT1aR gene knockout
185 improved adipose histomorphology and inhibited adipocyte hypertrophy.

186 **Fig 2. AT1aR knockout improved epididymal histomorphology induced by high fat diet.** A,
187 B: Body weight of rats was recorded weekly and body weight gain was calculated by weight increase
188 in 12 weeks. C: Physical morphology of epididymal fat; D: Epididymal fat index (showed as
189 epididymal fat weight/body weight). E: Adipocyte morphology was visualized by HE staining and
190 adipocyte area were calculate by Image J. * $p < 0.05$ vs WT-ND rats; # $p < 0.05$ vs WT-HFD rats. Data
191 were presented as Mean \pm S.E.M. n = 6

192 **3.3 AT1aR gene knockout promoted adipose lipolysis**

193 The main function of white adipose tissue is to store energy in the form of triglycerides and the fat
194 mass is systematically regulated by lipid synthesis and decomposition. In order to know the underlining
195 mechanism by which AT1aR gene knockout inhibited adipocyte hypertrophy, we detected the
196 expressions of major enzymes for triglyceride synthesis and lipolysis in the adipose tissue. Fatty acid
197 synthase (FAS) and acetyl-CoA carboxylase (ACC) are rate-limiting enzymes involved in biosynthesis
198 of fatty acids, an important step of lipogenesis[18]. Gene expressions of FAS and ACC were measured
199 with QPCR and the results showed that there were no significant differences between WT and AT1aR^{-/-}
200 rats neither fed with normal diet nor with high-fat diet (Fig 3A, B). The hydrolysis of triglycerides is
201 initiated by adipose triglyceride lipase (ATGL)[19], and hormone sensitive lipase (HSL) is the main
202 hydrolase for triacylglycerol (TAG) and diacylglycerol (DAG)[20]. As showed in Fig 3C, protein
203 expression of ATGL and phosphorylation of HSL in AT1aR^{-/-} rats were much higher than those of WT
204 rats both in the normal and high-fat diet rats. Furthermore, the adipose tissue was cultured in the
205 DMEM for 24 hours and the levels of NEFAs and glycerol in the culture medium were detected.
206 Compared with WT rats fed with high-fat diet, the levels of NEFAs and glycerol released from adipose
207 tissue of high-fat diet AT1aR^{-/-} rats increased significantly (Fig 3D, E). These results proved that
208 AT1aR knockout improved adipose histomorphology in high-fat diet rats by promoting adipose
209 lipolysis, while did not affect lipid synthesis.

210 **Fig 3. AT1aR knockout promoted adipose lipolysis.** A, B: Gene expressions of key enzymes for
211 lipid synthesis in adipose tissue, FAS (A) and ACC (B). C: Protein expressions of adipose lipolysis
212 related enzymes, ATGL and HSL. D, E: Levels of NEFAs (D) and glycerol (E) in culture medium
213 released by adipose tissue within 24h. *p < 0.05 vs WT-ND rats; +p < 0.05 vs AT1aR^{-/-}-ND rats. Data
214 were presented as Mean ± S.E.M. n = 6

215 3.4 AT1aR knockout accelerated adipose energy expenditure and fatty acids oxidation

216 Subsequently, adipose lipid utilization was detected. Peroxisome proliferator activated receptor δ
217 (PPAR δ) is a transcription factor that promote oxidative metabolism in adipose[21] and deiodinase 2
218 (Dio2) could activate thyroid hormone to promote energy expenditure[22]. The results showed that by
219 comparison of WT rats fed with high-fat diet, the gene expressions of PPAR δ and Dio2 in adipose
220 tissue were significantly increased in high-fat diet AT1aR^{-/-} rats (Fig 4A, B), indicating increased
221 energy consumption adipose tissue of AT1aR^{-/-} rats. Besides, the levels of fatty acid oxidation in
222 adipose tissue were also measured. Peroxisome proliferator-activated receptors α (PPAR α) acts as a
223 transcription factor to regulate a series of genes involved in fatty acid oxidation like carnitine
224 palmitoyltransferase 1 (CPT1) [23, 24]. The results showed that the gene expressions of PPAR α and
225 CPT1 were significantly increased in AT1aR^{-/-} rats compared with WT rats fed with high fat diet.
226 However, there was not difference between the WT and AT1aR^{-/-} rats fed a normal diet (Fig 4C, D).
227 These results indicated enhanced fatty acid oxidation in high-fat diet AT1aR^{-/-} rats.

228 **Fig4. AT1aR knockout accelerated adipose energy expenditure and fatty acids oxidation.** A,
229 B: Gene expressions of PPAR δ (A) and Dio2 (B) in adipose tissue. C, D: Gene expressions of PPAR α
230 and CPT1 in adipose tissue. +p < 0.05 vs AT1aR^{-/-}ND rats. Data were presented as Mean \pm S.E.M. n
231 = 6

232 3.5 AT1aR knockout activated cAMP/PKA pathway

233 It has been reported that the binding of Ang II to AT1R activates Gi protein against the effect of
234 cAMP/PKA pathway[25]. As showed in Fig 5A and 5B, PKA and cAMP levels were significantly
235 increased in AT1aR^{-/-} rats fed with high-fat. Protein kinase A (PKA) that activated by cyclic adenosine
236 monophosphate (cAMP) mainly phosphorylates HSL to mediate adipose lipolysis [26]. Apart from

237 HSL, GSK-3 β is also an important phosphorylation substrate of PKA[27]. The phosphorylation level of
238 GSK-3 β in AT1aR^{-/-} rats was higher than WT rats both in the normal and high-fat diet (Fig 5A), further
239 confirmed the enhancement of PKA activity in AT1aR^{-/-} rats. These results suggested that gene
240 knockout of AT1aR could activate cAMP/PKA pathway.

241 **Fig 5. AT1aR knockout activated cAMP/PKA pathway.** A: Protein expressions of PKA, P-
242 GSK-3 β (ser9) and GSK-3 β in adipose tissue. B: cAMP levels in adipose tissue. C: The proposed
243 pathway for Ang II inhibiting adipose lipolysis. By binding to AT1R, Ang II activates inhibitory Gi
244 which in turn reduces cAMP production. As a result, PKA activation is limited and HSL
245 phosphorylation is decreased, leading to inhibitory triglyceride hydrolysis. +p < 0.05 vs AT1aR^{-/-}ND
246 rats. Data were presented as Mean \pm S.E.M. n = 6

247 4. Discussion

248 Obesity is the common pathological basis of many metabolic diseases and its mechanism
249 exploration has attracted more and more attention. RAS is generally considered acting in the regulation
250 of blood pressure and organism water-salt balance. However, clinical studies have demonstrated that
251 type 2 diabetes can be delayed by treatment with ACEI and ARB compared with other antihypertensive
252 drugs[28]. Besides, captopril, one of ACEI drugs, was showed to not only lower blood pressure but
253 also reduce the weight of high-fat diet rats[29]. These studies indicated that RAS plays an important
254 role in obesity and subsequent metabolic diseases, whereas the regulatory mechanism remains unclear.
255 In the present study, we found that the gene knockout of AT1aR improved high-fat diet induced obesity
256 by promoting lipolysis through cAMP/PKA pathway, providing new sight for the prevention and
257 treatment of obesity and related metabolic disorders.

258 As the primary peptide of the RAS, Ang II exerts its biological activity mainly through AT1R in

259 adipose tissue. Different from human beings, AT1R is coded by two gene subtypes, AT1aR and
260 AT1bR, in rodent mammals[30]. AT1aR has the most homology with human, mainly involved in the
261 vasoconstriction and blood pressure regulation. While AT1bR is related to the thirst response of
262 mammals and existed in certain areas of the central nervous system and adrenal tissues [31]. So, in the
263 present study, we constructed AT1aR^{-/-} rats to explore the relation between RAS and obesity.

264 Obesity is closely correlated with insulin resistance and diabetes. Besides storage energy, adipose
265 tissue also acts as an endocrine organ. In obesity, adipocytes secrete inflammatory adipokines which
266 damage insulin signaling pathway, resulting in disorders of glucose and lipid metabolism^[32]. Here, we
267 showed that AT1aR gene knockout improved glucose intolerance and insulin sensibility in high-fat diet
268 induced obese rats. Consistent with our results, Kengo Azushima et al. has demonstrated that
269 upregulation of AT1R-related protein (ATRAP), a protein limiting AT1R's effects by promoting its
270 internalization, could improve insulin resistance[17].

271 Lipid stocks in the adipose tissue fluctuate by lipid synthesis and lipolysis. Our results showed
272 that AT1aR gene knockout improved adipocyte hypertrophy in obese rats mainly by promoting
273 lipolysis. However, enhanced lipolysis increases circulatory NEFAs which leading to ectopic
274 deposition of lipids. Interestingly, serum levels of NEFAs were decreased in high-fat diet AT1aR^{-/-} rats
275 despite significant enhancement of lipolysis in adipose tissue. In this regard, energy expenditure and
276 NEFAs oxidation in adipose tissue were measured. The results demonstrated that genes expressions of
277 proteins involved in adipose tissue oxidative metabolism were elevated. Given that increasing lipolysis
278 in adipose tissue result in elevated circulating NEFAs, our results showed that AT1aR gene knockout
279 promoted adipose energy expenditure and fatty acids utilization, and thus lowering lipolysis-derived
280 circulating NEFAs levels.

281 By binding to AT1R, a G protein-coupled receptor, Ang II activates inhibitory Gi protein which
282 in turn decreases cAMP production[33, 34]. The cAMP/PKA pathway plays an important role in
283 energy balance and metabolic regulation. As an important second messenger, increased cellular cAMP
284 activates PKA which in turn phosphorylates HSL[35]. AT1aR gene knockout increased PKA protein
285 expression and cellular levels of cAMP in the adipose tissue. Activated PKA can be confirmed by
286 increased phosphorylation of GSK-3 β , a main phosphorylation substrate of PKA[27].

287 In conclusion, our results showed that RAS predominant peptide Ang II promoted adipocyte
288 hypertrophy by inhibition of cAMP/PKA and subsequent adipose lipolysis via binding to AT1aR.
289 However, AT1aR gene knockout activated cAMP/PKA signaling and elevated adipose lipolysis by
290 phosphorylation of HSL, and thus improving obesity and insulin resistance (Fig 5C). Our findings
291 emphasized the special role of RAS signaling in adipose tissue in the progress of obesity and associated
292 metabolic abnormalities, and provided potential drug target for their therapy.

293

294 **Acknowledgments**

295 Thanks for the support of Shanxi Key Subjects Construction (FSKSC), and Shanxi ‘1331 Project’
296 Key Subjects Construction.

297 **Author contributions**

298 **Aiyun Li:** Conceptualization, Methodology, Writing - Review & Editing. **Wenjuan Shi:**
299 Conceptualization, Methodology, Investigation, Writing - Original Draft. **Jin Wang:** Resources,
300 Project administration, Validation. **Xuejiao Wang:** Investigation, Software. **Yan Zhang:** Validation,
301 Software. **Zhandong Lei:** Data Curation, Software. **Xiangying Jiao:** Conceptualization, Writing -
302 Review & Editing, Supervision.

303

304 **References**

- 305 1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to
306 2030. *Int J Obes (Lond)*. 2008;32(9):1431-7. Epub 2008/07/09. doi: 10.1038/ijo.2008.102. PubMed
307 PMID: 18607383.
- 308 2. Ahmadian M, Duncan RE, Jaworski K, Sarkadi-Nagy E, Sul HS. Triacylglycerol metabolism in
309 adipose tissue. *Future Lipidol*. 2007;2(2):229-37. Epub 2007/04/01. doi: 10.2217/17460875.2.2.229.
310 PubMed PMID: 19194515; PubMed Central PMCID: PMCPMC2633634.
- 311 3. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. *J Clin Invest*.
312 2011;121(6):2094-101. Epub 2011/06/03. doi: 10.1172/JCI45887. PubMed PMID: 21633177; PubMed
313 Central PMCID: PMCPMC3104761.
- 314 4. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose Tissue Remodeling: Its Role in Energy
315 Metabolism and Metabolic Disorders. *Front Endocrinol (Lausanne)*. 2016;7:30. Epub 2016/05/06. doi:
316 10.3389/fendo.2016.00030. PubMed PMID: 27148161; PubMed Central PMCID: PMCPMC4829583.
- 317 5. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor
318 antagonism reduces insulin resistance in obese Zucker rats. *Hypertension*. 2001;38(4):884-90. Epub
319 2001/10/20. doi: 10.1161/hy1101.092970. PubMed PMID: 11641303.
- 320 6. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, et al. Angiotensin II type-1 receptor blocker
321 valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. *Hypertension*.
322 2004;43(5):1003-10. Epub 2004/03/24. doi: 10.1161/01.HYP.0000125142.41703.64. PubMed PMID:
323 15037562.
- 324 7. Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, et al. Increased energy expenditure,

- 325 dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. *Cell Metab.*
326 2007;6(6):506-12. Epub 2007/12/07. doi: 10.1016/j.cmet.2007.10.011. PubMed PMID: 18054319;
327 PubMed Central PMCID: PMCPMC2174204.
- 328 8. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depot-specific modulation of
329 angiotensinogen gene expression in diet-induced obesity. *Am J Physiol Endocrinol Metab.*
330 2004;286(6):E891-5. Epub 2004/01/30. doi: 10.1152/ajpendo.00551.2003. PubMed PMID: 14749209.
- 331 9. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the
332 metabolic syndrome. *Circulation.* 2004;110(11):1507-12. Epub 2004/09/15. doi:
333 10.1161/01.CIR.0000141736.76561.78. PubMed PMID: 15364819.
- 334 10. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, et al. The adipose-tissue
335 renin-angiotensin-aldosterone system: role in the metabolic syndrome? *The International Journal of*
336 *Biochemistry & Cell Biology.* 2003;35(6):807-25. doi: 10.1016/s1357-2725(02)00311-4.
- 337 11. Kalupahana NS, Massiera F, Quignard-Boulangé A, Ailhaud G, Voy BH, Wasserman DH, et al.
338 Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose
339 intolerance, and insulin resistance. *Obesity (Silver Spring).* 2012;20(1):48-56. Epub 2011/10/08. doi:
340 10.1038/oby.2011.299. PubMed PMID: 21979391; PubMed Central PMCID: PMCPMC4465436.
- 341 12. Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensinogen gene expression in adipose
342 tissue: analysis of obese models and hormonal and nutritional control. *Am J Physiol.* 1997;273(1 Pt
343 2):R236-42. Epub 1997/07/01. doi: 10.1152/ajpregu.1997.273.1.R236. PubMed PMID: 9249555.
- 344 13. Pahlavani M, Kalupahana NS, Ramalingam L, Moustaid-Moussa N. Regulation and Functions of
345 the Renin-Angiotensin System in White and Brown Adipose Tissue. *Compr Physiol.* 2017;7(4):1137-50.
346 Epub 2017/09/16. doi: 10.1002/cphy.c160031. PubMed PMID: 28915321; PubMed Central PMCID:

347 PMCPMC7561006.

348 14. Jing F, Mogi M, Horiuchi M. Role of renin–angiotensin–aldosterone system in adipose tissue
349 dysfunction. *Molecular and Cellular Endocrinology*. 2013;378(1-2):23-8. doi:
350 10.1016/j.mce.2012.03.005.

351 15. Wang CH, Li F, Takahashi N. The renin angiotensin system and the metabolic syndrome. *Open*
352 *Hypertens J*. 2010;3:1-13. Epub 2010/12/07. doi: 10.2174/1876526203010001. PubMed PMID:
353 21132096; PubMed Central PMCID: PMCPMC2995894.

354 16. de Kloet AD, Pioquinto DJ, Nguyen D, Wang L, Smith JA, Hiller H, et al. Obesity induces
355 neuroinflammation mediated by altered expression of the renin-angiotensin system in mouse
356 forebrain nuclei. *Physiol Behav*. 2014;136:31-8. Epub 2014/02/11. doi:
357 10.1016/j.physbeh.2014.01.016. PubMed PMID: 24508821; PubMed Central PMCID:
358 PMCPMC4125551.

359 17. Azushima K, Ohki K, Wakui H, Uneda K, Haku S, Kobayashi R, et al. Adipocyte - Specific
360 Enhancement of Angiotensin II Type 1 Receptor - Associated Protein Ameliorates Diet - Induced
361 Visceral Obesity and Insulin Resistance. *Journal of the American Heart Association*. 2017;6(3). doi:
362 10.1161/jaha.116.004488.

363 18. Wakil SJ, Stoops JK, Joshi VC. Fatty acid synthesis and its regulation. *Annu Rev Biochem*.
364 1983;52:537-79. Epub 1983/01/01. doi: 10.1146/annurev.bi.52.070183.002541. PubMed PMID:
365 6137188.

366 19. Schreiber R, Xie H, Schweiger M. Of mice and men: The physiological role of adipose triglyceride
367 lipase (ATGL). *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*.
368 2019;1864(6):880-99. doi: 10.1016/j.bbalip.2018.10.008.

- 369 20. Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS. Regulation of Lipolysis in
370 Adipocytes. Annual Review of Nutrition. 2007;27(1):79-101. doi:
371 10.1146/annurev.nutr.27.061406.093734.
- 372 21. Roberts LD, Murray AJ, Menassa D, Ashmore T, Nicholls AW, Griffin JL. The contrasting roles of
373 PPARdelta and PPARgamma in regulating the metabolic switch between oxidation and storage of fats
374 in white adipose tissue. Genome Biol. 2011;12(8):R75. Epub 2011/08/17. doi: 10.1186/gb-2011-12-8-
375 r75. PubMed PMID: 21843327; PubMed Central PMCID: PMC3245615.
- 376 22. Castillo M, Hall JA, Correa-Medina M, Ueta C, Kang HW, Cohen DE, et al. Disruption of thyroid
377 hormone activation in type 2 deiodinase knockout mice causes obesity with glucose intolerance and
378 liver steatosis only at thermoneutrality. Diabetes. 2011;60(4):1082-9. Epub 2011/02/22. doi:
379 10.2337/db10-0758. PubMed PMID: 21335378; PubMed Central PMCID: PMC3064082.
- 380 23. Sun B, Jia Y, Hong J, Sun Q, Gao S, Hu Y, et al. Sodium Butyrate Ameliorates High-Fat-Diet-
381 Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor alpha-
382 Mediated Activation of beta Oxidation and Suppression of Inflammation. J Agric Food Chem.
383 2018;66(29):7633-42. Epub 2018/07/03. doi: 10.1021/acs.jafc.8b01189. PubMed PMID: 29961332.
- 384 24. Yoon S, Kim J, Lee H, Lee H, Lim J, Yang H, et al. The effects of herbal composition
385 Gambigyeongsinwhan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima
386 fatty rats and HepG2 cells. J Ethnopharmacol. 2017;195:204-13. Epub 2016/11/16. doi:
387 10.1016/j.jep.2016.11.020. PubMed PMID: 27845265.
- 388 25. Crajoinas RO, Polidoro JZ, Carneiro de Moraes CP, Castelo-Branco RC, Girardi AC. Angiotensin II
389 counteracts the effects of cAMP/PKA on NHE3 activity and phosphorylation in proximal tubule cells.
390 Am J Physiol Cell Physiol. 2016;311(5):C768-C76. Epub 2016/11/03. doi: 10.1152/ajpcell.00191.2016.

- 391 PubMed PMID: 27510906.
- 392 26. London E, Bloyd M, Stratakis CA. PKA functions in metabolism and resistance to obesity: lessons
393 from mouse and human studies. *J Endocrinol.* 2020;246(3):R51-R64. Epub 2020/06/03. doi:
394 10.1530/JOE-20-0035. PubMed PMID: 32485681; PubMed Central PMCID: PMC7385994.
- 395 27. Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, Mills GB. Phosphorylation and inactivation of
396 glycogen synthase kinase 3 by protein kinase A. *Proc Natl Acad Sci U S A.* 2000;97(22):11960-5. Epub
397 2000/10/18. doi: 10.1073/pnas.220413597. PubMed PMID: 11035810; PubMed Central PMCID:
398 PMCPMC17277.
- 399 28. Abuissa H, Jones PG, Marso SP, O'Keefe JH, Jr. Angiotensin-converting enzyme inhibitors or
400 angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized
401 clinical trials. *J Am Coll Cardiol.* 2005;46(5):821-6. Epub 2005/09/06. doi: 10.1016/j.jacc.2005.05.051.
402 PubMed PMID: 16139131.
- 403 29. de Kloet AD, Krause EG, Kim DH, Sakai RR, Seeley RJ, Woods SC. The effect of angiotensin-
404 converting enzyme inhibition using captopril on energy balance and glucose homeostasis.
405 *Endocrinology.* 2009;150(9):4114-23. Epub 2009/06/06. doi: 10.1210/en.2009-0065. PubMed PMID:
406 19497971; PubMed Central PMCID: PMC2736089.
- 407 30. Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK, Dzau VJ. Cloning, characterization, and
408 expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. *Biochemical and*
409 *Biophysical Research Communications.* 1992;185(1):253-9. doi: 10.1016/s0006-291x(05)80983-0.
- 410 31. Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor
411 1A and 1B in mouse. *Am J Physiol.* 1994;267(2 Pt 1):E260-7. Epub 1994/08/01. doi:
412 10.1152/ajpendo.1994.267.2.E260. PubMed PMID: 8074205.

413 32. Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al. Pathogenic
414 potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased
415 visceral adiposity. *Expert Rev Cardiovasc Ther.* 2008;6(3):343-68. Epub 2008/03/11. doi:
416 10.1586/14779072.6.3.343. PubMed PMID: 18327995.

417 33. Liu FY, Cogan MG. Angiotensin II stimulates early proximal bicarbonate absorption in the rat by
418 decreasing cyclic adenosine monophosphate. *J Clin Invest.* 1989;84(1):83-91. Epub 1989/07/01. doi:
419 10.1172/JCI114174. PubMed PMID: 2544631; PubMed Central PMCID: PMCPMC303956.

420 34. Anand-Srivastava MB. Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and
421 Oxidative Stress. *Curr Cardiol Rev.* 2010;6(4):298-308. Epub 2011/11/02. doi:
422 10.2174/157340310793566046. PubMed PMID: 22043206; PubMed Central PMCID:
423 PMCPMC3083811.


424 35. Schweiger M, Schreiber R, Haemmerle G, Lass A, Fledelius C, Jacobsen P, et al. Adipose
425 triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue
426 triacylglycerol catabolism. *J Biol Chem.* 2006;281(52):40236-41. Epub 2006/11/01. doi:
427 10.1074/jbc.M608048200. PubMed PMID: 17074755.

428







429


430 **Supporting information**

431 **S1 Fig.** PCR results for AT1aR^{-/-} rats and WT rats. M: marker; N: negative control; P: positive control







Figure






Figure




Figure


A




bioRxiv preprint doi: <https://doi.org/10.1101/2022.04.07.487533>; this version posted April 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.





B



C



A



Figure